By Rob Braddock
A pharmaceutical technology transfer can look complete on a project schedule while the receiving site is still not ready to run the process reliably. The real test is whether the site can execute the process, control its risks, investigate problems, and sustain routine production with approved systems and trained people.
What Pharmaceutical Technology Transfer Must Accomplish
ICH Q10 states that technology transfer should move product and process knowledge between development and manufacturing, or between manufacturing sites, so the product can be realized. That knowledge supports the manufacturing process, control strategy, process validation approach, and continued improvement. The transfer should therefore produce usable operating knowledge, not just a document package.
FDA’s process validation guidance uses a lifecycle approach that begins with process design, continues through process qualification, and extends into continued process verification. A transfer plan should connect these stages instead of treating engineering runs, validation, and commercial production as separate projects.
Build a Readiness Matrix Before Setting the Date
Create one cross functional matrix with a clear owner, required evidence, due date, and status for every item. At minimum, review these six areas:
- Process knowledge: Critical quality attributes, material attributes, process parameters, proven acceptable ranges, known failure modes, and scale dependent risks.
- Facilities and equipment: Capacity, utilities, containment, cleaning, calibration, maintenance, qualification, computerized systems, and spare parts.
- Materials and suppliers: Specifications, approved sources, lead times, storage conditions, sampling plans, and change notification requirements.
- Methods and records: Analytical method transfer, batch records, procedures, data collection, deviation pathways, and record review responsibilities.
- People: Staffing by shift, role clarity, training, qualification, technical support, and escalation coverage.
- Quality and regulatory: Change controls, risk assessments, validation strategy, filing commitments, stability plans, release requirements, and quality agreements.
Make the Gap List Useful
A long list of open items does not show whether the transfer is safe to advance. Classify each gap by product quality risk, compliance risk, supply impact, and dependency. Define what evidence is required for closure. A purchase order is not proof that equipment is ready. A drafted procedure is not proof that operators can perform it.
Use readiness gates before engineering runs, process performance qualification, and routine manufacture. Each gate should state who can approve progression and which unresolved items require formal risk acceptance. This keeps schedule pressure from turning assumptions into undocumented decisions.
Use Runs to Learn, Not Only to Pass
Engineering and demonstration runs should test the receiving site’s actual conditions. Capture interventions, holds, yield losses, equipment limits, sampling delays, and operator observations. Compare results with development and sending site knowledge. If new variables appear, assess whether the control strategy, instructions, training, or validation plan must change.
FDA explains that the number of validation batches should have a sound, science based rationale rather than relying on a fixed rule. The agency’s current CGMP questions and answers emphasizes process understanding and reproducibility at scale.
Plan for the First Routine Batches
Technology transfer is not finished when qualification ends. Define enhanced monitoring for early commercial batches, including process performance, deviations, maintenance events, laboratory turnaround, yield, and review time. Set review points and criteria for returning to normal oversight. Assign ownership for remaining knowledge gaps and improvement actions.
The ICH Q10 pharmaceutical quality system guideline links technology transfer with monitoring, CAPA, change management, and management review. Using those systems early helps the receiving site maintain control after the project team steps back.
A Practical Readiness Decision
Before authorizing the next phase, ask one direct question: Can the receiving site demonstrate, with approved evidence, that it understands the process and can control the important sources of variation? If the answer depends on assumptions, undocumented knowledge, or support that will not be available during routine production, the transfer is not ready.
Support for Manufacturing Technology Transfer
PharmExcel helps pharmaceutical and life science teams assess transfer readiness, organize cross functional gaps, clarify operating responsibilities, and prepare facilities and manufacturing systems for execution. Review our consulting services and pharmaceutical manufacturing site assessment guide, or contact Rob Braddock to discuss a planned transfer or a project that is slipping.